Genentech's Perjeta regimen gets FDA Priority Review for HER2-positive early stage br

[News]

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application for the use of a Perjeta (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with HER2-positive early stage breast cancer.

More... (http://www.news-medical.net/news/20130702/Genentechs-Perjeta-regimen-gets-FDA-Priority-Review-for-HER2-positive-early-stage-breast-cancer.aspx)

[karen z]

Interesting as are many of the news postings today.

['lizbeth]

Does anyone know if the neoadjuvant treatment is solely Perjeta without chemo, and what do they consider early stage? Is it tumor size below 1cm?